文献速递免疫规划卫生政策与健康促进传染病防控与疫情报告

奥密克戎变异株时期COVID-19疫苗有效性的活系统综述:对未来大流行的启示

Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.
PubMed 文献 · Vaccine · 2026-08-13

结果显示疫苗对重症或危重症有强保护作用,尤其mRNA疫苗,但多数结果存在中度或严重偏倚风险。

要点

  • 疫苗对奥密克戎所致重症或危重症有强保护,尤其mRNA疫苗。
  • 多数疫苗有效性估计存在中度或严重偏倚风险,主要混杂。
  • 未来大流行准备需标准化研究方案和稳健数据链接。

核心结论

  • 接种疫苗对奥密克戎变异株所致重症或危重症有强保护作用,尤其mRNA疫苗。
  • 多数疫苗有效性估计存在中度或严重偏倚风险,主要关注混杂。

研究设计与样本

  • 活系统综述,由世界卫生组织委托,每周检索7个数据库至2022年12月31日。
  • 使用ROBINS-I工具评估疫苗有效性估计的偏倚风险。

主要发现

  • 79项研究中,针对无症状SARS-CoV-2感染36项(45.6%),有症状COVID-19 31项(39.2%),重症或危重症COVID-19 53项(67.1%),全因死亡2项(2.5%)。
  • 多数结果被判定为中度偏倚风险(361,18%)或严重偏倚风险(1591,78%)。
  • 系统比较疫苗平台、剂量方案和人群的疫苗性能,聚焦于重症或危重症COVID-19。

临床怎么用

  • 未来大流行准备需重视标准化研究方案。
  • 需建立疫苗接种、检测和结局之间的稳健数据链接。
  • 需为多样化观察性设计建立经过验证的偏倚风险评估框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reliable evidence on COVID-19 vaccine effectiveness during the period of Omicron variant predominance was essential to inform global vaccination strategies. Our living systematic review, commissioned by the World Health Organization (WHO), was established to provide an ongoing synthesis and critical appraisal of comparative observational studies evaluating the effectiveness of vaccines against COVID-19/SARS-CoV-2 infection caused by the Omicron variant. Weekly searches covering seven databases up to 31 December 2022 sought evidence for WHO-approved vaccine platforms, including mRNA vaccines (BNT162b2, mRNA-1273), adenoviral vector vaccines (ChAdOx1-S, SII-ChAdOx1 nCoV-19, Ad26.COV2·S, Gam-COVID-Vac) and inactivated virus vaccines (CoronaVac, BBV-152). We used the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool to assess the validity of estimates of vaccine effectiveness. The review included 79 studies of over 53 million individuals, contributing 2032 estimates of vaccine effectiveness against asymptomatic SARS-CoV-2 infection (36; 45.6%), symptomatic COVID-19 (31; 39.2%), severe or critical COVID-19 (53; 67.1%) and all-cause mortality (2; 2.5%). Structured comparisons of vaccine performance across platforms, dosing schedules and populations, focussed on severe or critical COVID-19 disease. Vaccination was observed to be strongly protective against severe or critical disease caused by the Omicron variant, particularly for mRNA vaccines. Most results were judged to be at moderate risk of bias (361, 18%) or at serious risk of bias (1591, 78%) with the principal concern being confounding. We discuss implications for future pandemic preparedness, including the importance of standardized study protocols; robust data linkage between vaccination, testing and outcomes; and validated risk-of-bias frameworks for diverse observational designs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kazi F, Shapland CY, Spiga F, et al. Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant. Vaccine. 2026. PMID: 42594644. doi:10.1016/j.vaccine.2026.128993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。